Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity


Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved November 13, 2020 (received for review September 1, 2020)

Multiple sclerosis (MS) disease risk is associated with reduced sun-exposure. This study assessed the relationship between measures of sun exposure (vitamin D [vitD], latitude) and MS severity in the setting of two multicenter cohort studies (n = 946, n = 990). Additionally, effect-modification by medication and photosensitivity-associated MCTR variants was assessed. High serum vitD was associated with a reduced MS severity score (MSSS), reduced risk for relapses, and lower disability accumulation over time. Low latitude was associated with higher vitD, lower MSSS, fewer gadolinium-enhancing lesions, and lower disability accumulation. The association of latitude with disability was lacking in IFN-β-treated patients. In carriers of MCTR1rs1805008(T), who reported increased sensitivity toward sunlight, lower latitude was associated with higher MRI activity, whereas for noncarriers there was less MRI activity at lower latitudes. In a further exploratory approach, the effect of ultraviolet (UV)-phototherapy on the transcriptome of immune cells of MS patients was assessed using samples from an earlier study. Phototherapy induced a vitD and type I IFNs signature that was most apparent in monocytes but that could also be detected in B and T cells. In summary, our study suggests beneficial effects of sun exposure on established MS, as demonstrated by a correlative network between the three factors: Latitude, vitD, and disease severity. However, sun exposure might be detrimental for photosensitive patients. Furthermore, a direct induction of type I IFNs through sun exposure could be another mechanism of UV-mediated immune-modulation in MS.

Multiple sclerosis (MS), characterized by demyelinating lesions, is the most common neuroinflammatory disease of the central nervous system and presumably of autoimmune origin (1). In most cases, the disease is diagnosed at a young age, predominantly occurs in women, and follows a relapsing-remitting course, which can be superseded by a secondary, progressive stage (2). Etiologically, environmental factors have been shown to play an important role (3) and insufficient sunlight exposure has been suspected to be critical for the initial development of MS (4). The best characterized mediator of ultraviolet radiation (UVR)-dependent effects is vitamin D (vitD), which is generated from its precursor 7-dehydrocholesterol (7-DHC) in the skin, further metabolized in the liver and kidney, and that exerts its functions in its active form 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], also known as calcitriol (5). Precursors of active vitD can also be found in food in the form of ergocalciferol (or vitamin D2), which is, however, of little relevance for total serum vitD levels (6). For MS, low vitD levels have been shown to be associated with disease risk (7, 8) and Mendelian randomization studies hint toward a causal role for vitD (9). However, it is possible that alternative UVR-dependent pathways play a role as well (11). A study by Langer-Gould et al. (12) suggested that serum vitD is only a risk factor for MS in Whites, but not in people of color, although lifetime UVR-exposure was associated with reduced multiple sclerosis severity.

Significance

Low sunlight exposure and low vitamin D (vitD) levels are risk factors for the development of multiple sclerosis. However, there is still an ongoing debate, whether sunlight and vitD also modulate disease severity and worsening. Observational studies suggested vitD-dependent effects, but prospective supplementation studies have so far been inconclusive and reverse causality cannot be excluded as a source of bias. By using the sun-exposure measures vitD and latitude, we show correlations between vitD/latitude, vitD/disease severity, and latitude/disease severity in two multicentric cohorts. Although vitD cannot be proven as the causal factor, we provide evidence for clinically relevant effects of sunlight exposure. Furthermore, this study suggests sunlight-triggered pathways other than vitD could play additional and modular roles, as well.


This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1H.W. and N.S. contributed equally to this work.

2To whom correspondence may be addressed. Email: nicholas.schwab@ukuemuenster.de or heinz.wiend@ukuemuenster.de

3Complete lists of the German Competence Network Multiple Sclerosis (KKNMS) and BIONAT study investigators can be found in SI Appendix.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2018457118/-/DCSupplemental.

Published December 29, 2020.
with reduced risk in both, arguing against vitD as the mediator of UVR-effects. Hedström et al. (13) report from a large population-based study that besides vitD-dependent effects, vitD-independent effects of UVR also play a role. Results from the PhotoCIS (Phototherapy for Clinically Isolated Syndrome [CIS]) trial and its post hoc analysis suggest effects of UVR even in patients with a serum vitD status of ≥80 ng/mL (14, 15). Furthermore, it is still a topic of debate whether UVR/vitD only modulate disease risk, or if disease severity of established MS is affected, as well. In mouse models, UVR was shown to ameliorate disease, but this was independent of vitD and its receptor (16–19). Human observational studies suggested an influence of vitD on disease activity (20, 21) and prospective trials also suggested an effect on the formation of lesions, but the primary endpoints of supplementation studies have not been met so far, raising doubt about the role of vitD in ongoing disease (22–24). It has also been argued that reverse causation could influence the results from observational studies (i.e., low vitamin D could be caused by disease activity rather than vice versa) (4).

Reports on the effect of latitude (which can be regarded as an independent measure of sun-exposure) on disease severity are scarce and could either not identify any effects or showed contradictory effects (25, 26). Noteworthy, besides the assumed main effects of UVR and vitD on MS severity, there might be factors that could alter the effects of UVR/vitD. Medication main effects of UVR and vitD on MS severity, there might be contradictory effects (25, 26). Noteworthy, besides the assumed independent measure of sun-exposure) on disease severity are also been argued that reverse causation could influence the results from observational studies (i.e., low vitamin D could be caused by disease activity rather than vice versa) (4).

Results

Cohort Characteristics. For the NationMS cohort, data of 946 treatment-naive patients at baseline with CIS or relapsing-remitting multiple sclerosis (RRMS) were acquired (disease duration <2 y). The study procedure is shown in Fig. 1. Baseline characteristics are described in SI Appendix, Table S1. Genotyping for MC1R was successful and passed quality control (QC) for 883 (97.25%) of the 908 patients that had full demographic and clinical information available. The most common MC1R variant allele was rs1805088:T (n = 148 of 883, 16.76% with ≥1 risk allele, minor allele frequency [MAF] = 8.60%), followed by rs2228479:A (n = 140 of 883, 15.86% with ≥1 risk allele, MAF = 8.10%), and rs855479:A (n = 76 of 883, 8.61% with ≥1 risk allele, MAF = 4.42%). Patients were subjected to regular follow-ups. In total, for 798 patients, longitudinal data were available (Fig. 1). Of these, 148 (18.55%) patients remained untreated after baseline assessment, while 650 (81.46%) received treatment. The most prescribed medication was IFN-β (n = 364, 45.61% of all patients, including untreated) (SI Appendix, Table S2). A change in medication was recorded for 233 patients (29.20% ever changed). Moreover, 355 patients (44.9%) reported a relapse in the time after baseline assessment with a median time to relapse of 245 d (interquartile range = 102.0–470.5). For another 671 patients, disability was assessed 2 y after baseline, and the median change in expanded disability status scale (EDSS) was 0 (interquartile range = −0.5–0.5), with 233 patients (34.72%) who presented with an increase after those 2 y, 220 (32.79%) patients with a decrease, and 218 (32.49%) whose EDSS remained unchanged.

For the BIONAT cohort, data of 990 MS patients at their baseline assessment were acquired (Fig. 1). Full information on demographics, clinical subtype, medication, and the multiple sclerosis severity score (MSSS) were available for 808 patients (81.62%). Most patients had already received therapy before the baseline assessment. The most prescribed medication was IFN-β (59.77%) (SI Appendix, Table S2).

The characteristics of the five patients treated with UVB-phototherapy were previously published (18). Two of the patients were treated with IFN-β, one with Glatirameracetate (GA), one with Natalizumab, and one had not received any treatment. All patients with available biomaterial were included for this study and there were no specific selection criteria besides those already published in Breuer et al. (18).

Latitude and Prior Medication Determine Serum vitD Levels. With decreasing latitude, the amount of UVR reaching the earth’s surface increases; thus, latitude can be regarded as a measure of sun exposure. Indeed, a north–south gradient of UVR can be observed along the latitude axis in both Germany and France, with an increase in average yearly UVR of about twofold from the north of Germany to the south of France, as measured by NASA satellite data (Fig. 24). To demonstrate that lower latitude also correlates with higher actual UVR exposure on a population level, the correlation between latitude and serum vitD levels was tested in both cohorts. As expected, lower latitude was associated with higher vitD levels (β = −0.56, 95% confidence interval [CI] = [−1.030 to −0.090], P = 0.020) in the NationMS cohort. Consistent with the results from the NationMS cohort, in the BIONAT cohort lower latitude was also associated with higher vitD levels (β = −0.44, 95% CI = [−0.87 to −0.018], P = 0.041) (SI Appendix, Fig. S1 A and B). However, not all patients from the BIONAT cohort were untreated and IFN-β treatment has been shown to modulate vitD levels, potentially by decreasing serum cholesterol, which in turn modulates the amount of the vitD-precursor 7-DHC (27, 29). In a subgroup analysis of patients who had received IFN-β therapy, there seemed to be no effect of latitude on vitD levels, while untreated and GA-treated patients showed the expected increase of vitD as latitude decreases (SI Appendix, Fig. S1C).

In line with previous reports, IFN-β-treated patients also had higher vitD levels than therapy-naive patients (β = 4.020, 95% CI = [0.450–7.560], P = 0.031) (SI Appendix, Fig. S1D) (29).

Low vitD Levels and High Latitude Are Associated with Clinical Disease Severity. Based on the available evidence before the start of the study, the association between latitude, vitD, and
clinical severity was assessed (Fig. 2). In the NationMS cohort vitD levels were associated with lower disability, as assessed by the MSSS ($\beta = -0.014$, 95% CI $= [-0.026$ to $-0.002], P = 0.021$). Higher latitude (corresponding to lower sun exposure) was associated with worse MSSS scores in the NationMS cohort ($\beta = 0.092$, 95% CI $= [-0.016$ to $-0.168], P = 0.018$) (Fig. 2A). A similar result was obtained when substituting latitude by satellite-derived UVR estimates ($\beta = 0.016, 95\% \text{ CI} = [0.005$ to $0.0283], \text{ interaction-p} = 0.042$). Subsequent subgroup analyses confirmed that higher latitude was associated with a worse MSSS in patients, whose last medication was not IFN-β ($\beta = 0.115$, 95% CI $= [0.001$ to $0.227], P = 0.047$), while patients treated with IFN-β did not show this effect ($\beta = -0.048$, 95% CI $= [-0.141$ to $-0.045], P = 0.310$) (Fig. 2C).

The Association of Latitude with Disability Is Absent in Patients Treated with IFN-β. The hypotheses were then also tested in the BIONAT cohort. Here, higher vitD levels showed an association with lower disability as well ($\beta = -0.022$, 95% CI $= [-0.037$ to $-0.007], P = 0.007$) (Fig. 2D). However, in contrast to the results from the NationMS cohort, there was no clear trend for an effect of latitude on the MSSS ($\beta = -0.004$, 95% CI $= [-0.076$ to $-0.068], P = 0.913$). As not all BIONAT patients were therapy-naïve at baseline and IFN-β therapy has been shown to modulate vitD synthesis, but also to eradicate the association between vitD and severity measures, it was hypothesized that the missing effect of latitude could also be due to confounding by IFN-β therapy (28–30). Interaction analyses indeed showed that the effect of latitude on disability was significantly different depending on IFN-β treatment status ($\beta = 0.145$, 95% CI $= [0.005$ to $0.283], \text{ interaction-p} = 0.042$). Subsequent subgroup analyses confirmed that higher latitude was associated with a worse MSSS in patients, whose last medication was not IFN-β ($\beta = 0.115$, 95% CI $= [0.001$ to $0.227], P = 0.047$), while patients treated with IFN-β did not show this effect ($\beta = -0.048$, 95% CI $= [-0.141$ to $-0.045], P = 0.310$) (Fig. 2E).

High vitD and Low Latitude Are Associated with Reduced Risk for Relapses and Disability Accumulation. To further test the predictive capacity of vitD and latitude with regard to accumulation of disease burden, data on confirmed relapses after baseline in the NationMS cohort were assessed (Fig. 3). In a mixed-effects Cox regression vitD (for statistical inference treated as continuous variable) reduced the risk for a relapse by 1% for every 1 ng/mL of serum vitD at baseline (hazard ratio [HR] $= 0.988$, 95% CI $= [0.978$ to $0.999], P = 0.028$). For the purpose of visualization, vitD was grouped into three categories: 1) The 20% of patients with the highest vitD levels ($\geq 30.31$ ng/mL); 2) the 20% of patients with the lowest vitD levels ($\leq 10.63$ ng/mL); and 3) the remaining patients. The proportion of relapses was reduced by 22% when comparing patients with low vitD levels ($\leq 10.63$ ng/mL) to patients with the highest vitD levels ($\geq 30.31$ ng/mL) (Fig. 3A). In the NationMS cohort, vitD levels were associated with lower disability, as assessed by the MSSS ($\beta = 1.08$, 95% CI $= [1.01$ to $1.16], P = 0.030$) (Fig. 2C).

**Fig. 1.** Study flow chart. Data of 946 therapy-naïve patients were acquired for the NationMS cohort and data of 990 BIONAT patients with a history of previous medication for MS have been acquired. Datasets were filtered for missing information with 908 NationMS and 808 BIONAT patients remaining at baseline. For the analysis of disease severity, BIONAT patients were further excluded when information on site of first event was unknown/unavailable (remaining total $n = 611$, $n$ for remaining patients with available information on serum vitD $= 451$). To assess the influence of sun-exposure measures on serum vitD levels, this information was not necessary and $n = 594$ patients were assessed. For NationMS, longitudinal information on relapses was available for $n = 798$ and information on disability 2 years after baseline was available for 671 patients.
with the lowest vitD levels (<10.86 ng/mL); and 3) the patients in between (Fig. 3A). This categorization is also close to common definitions of optimal (≥30 ng/mL) and deficient (<10 ng/mL) vitD levels (36, 37). As categorization exclusively served the purpose of visualization, results from statistical models were not influenced by this and relied on continuous scale serum vitD.

Furthermore, baseline vitD was associated with a lower grade of disability accumulation, as measured by the ΔEDSS (β = −0.006, 95% CI = [−0.012 to −0.0003], P = 0.046) (Fig. 3B). Latitude showed no significant effect on the risk for relapses (Fig. 3C). However, in line with the results from the baseline analysis, lower latitude was associated with significantly lower ΔEDSS (β = 0.67, 95% CI = [0.026–0.106], P = 0.001) (Fig. 3D).

**Discussion**

High latitude has been identified as a major risk factor for the development of MS (4). This association is suspected to be mediated by low exposure to UVR and subsequent low vitD levels. Although this is a worldwide phenomenon, there are exceptions to the rule. An unexpectedly high MS prevalence has been described for the island of Sardinia, despite high exposure to beneficial environmental factors like UVR, but also a seafood-rich diet. This exemplifies the importance of the genetic background, especially in historically rather isolated populations. Environmental factors are assumed to contribute more to overall MS risk than genetics; certain genetic compositions seem to be able to invert this balance (3, 38). Notably, populations like the Maori, Amerindian, and Inuit have been described to have a low MS risk, despite living in high-risk areas, which is of relevance for this study as in these populations hyporesponsive MC1R variants are rare (39).

Besides the risk to develop MS, it is still a topic of debate whether UVR, vitD, or other UVR-dependent pathways, have an influence on disease severity and worsening over time, as well. Most work has focused on vitD and only few studies investigated alternative UVR-mediated pathways, although several candidate molecules have been proposed to mediate UVR-effects (e.g., nitric oxide, cis-urocanic acid, and tryptophan metabolites) (11, 40, 41). In the present study, data of two large, independent multicenter cohorts was used to test the association between latitude and vitD with MS disease severity. In this regard, the phenomenon of UVR-dependent effects by medication and photosensitivity-associated MC1R missense alleles was investigated as well. To explore by which mechanisms UV or UVR could exert immunomodulation in MS, next-generation sequencing was performed to assess the UVB phototherapy-induced changes in immune cells in a small group of patients.

In line with previous studies, we observed lower disease severity and a lower tendency toward disease worsening in patients with higher vitD levels in the NationMS cohort (4). Cutoffs for immunomodulation by vitD have been discussed previously in the post hoc analyses of the BENEFIT trial, suggesting ≥50 nmol/mL (equal to 20 ng/mL) to sensibly discriminate patients with low or high risk for disease activity and progression (20). Furthermore, results from BEYOND indicate that for optimal immunomodulation an even higher serum vitD status (≥100 nmol/mL) might be necessary (31). In line with these observations, our study indicates a linear relationship with no natural cutoff. Furthermore, confounding of our results by genetic predisposition is unlikely, as two large studies showed no interaction between the effects of UVR-vitD and HLA-DRB1*15:01, a major genetic risk factor for MS (31, 42).

Expectedly, vitD levels were also strongly associated with latitude. Therefore, latitude itself is a sound proxy for sun exposure on a population level, especially if adjusted for the sampling month as well. Consistently, latitude also showed a significant association with disease severity and worsening in the NationMS cohort. Confirming this, substituting a center’s latitude by satellite-derived vitD-estimates and...
Influence of sun-exposure measures on clinical severity. (Fig. 2.)

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.

Fig. 2. Influence of sun-exposure measures on clinical severity. (A) Map of 1-y averaged and erythemically weighted radiation reaching the earth's surface for Germany and France for the year 2015. White dots represent the locations of the medical centers that contributed participants to either the NationMS (only Germany) or the BIONAT (only France) cohort. (B) Dotplots for MSSS in relation to 25(OH)D$_3$ levels and latitude (of the patients’ medical center) with least-squares linear regression lines $\pm$ SE for NationMS ($n_{\text{nation}} = 761, n_{\text{Ga+}} = 908$). (C) Dotplot for Gd-enhancing lesions in relation to 25(OH)D$_3$ levels ($n = 761$) and latitude ($n = 908$) for the NationMS cohort. Left y axis corresponds to the dotplot displaying observed counts; right y axis corresponds to the red line displaying mean number of lesions $\pm$ SE. (D) Dotplot for MSSS in relation to 25(OH)D$_{2+3}$ with least-squares linear regression line $\pm$ SE for BIONAT. (E) Dotplots for MSSS in relation to latitude stratified by previous treatment ($n_{\text{IFN-\beta}} = 363, n_{\text{NAIVE/GA}} = 248$) with least-squares regression line $\pm$ SE. Analyses for NationMS are adjusted for age, sex, BMI, smoking, alcohol consumption, clinical subtype, neurological site of first manifestation, month of assessment, and center. Analyses for BIONAT are adjusted for age, sex, neurological site of first manifestation, month of assessment, and center. Adjustment for center was omitted when analyzing the effect of latitude.
previously been identified to be regulated upon IFN-β therapy in RRMS patients who were classified as IFN-β therapy responders (49, 50). The down-regulation of AHR and TIPARP, known counteractors of type I IFN-signaling, further supports a direct up-regulation of type I IFNs through phototherapy (51). Mechanistically, it is possible that the type I IFN expression is modulated by vitD, as interactions between vitD and IFN-α/β have been described previously (28, 29, 52). This is also in line with reports showing that vitD and IFN-β–triggered gene expression partly overlaps (53).

Moreover, studies have proposed that UVR could also induce type I IFNs via nucleic acid-damage and induction of damage-associated molecular patterns that can be sensed by Toll-like receptors and the stimulator of IFN genes (54, 55). Interestingly, type I IFNs were also shown to be induced in the skin of patients in between) and complemented with a table displaying the number at risk over time (n = 715). (B) Dotplot for the change in EDSS (ΔEDSS) in relation to baseline 25(OH)D3 levels with least-squares linear regression line ± SE (n = 612). (C) Time-to-event curves displaying the proportion of relapse-free patients over time for the NationMS cohort grouped by latitude (north defined as greater than or equal to median latitude within the cohort = 50.85°N) and complemented with a table displaying the number at risk over time (n = 798). (D) Dotplot for the ΔEDSS in relation to latitude with least-squares regression line ± SE (n = 671). Analyses are adjusted for age, sex, BMI, smoking, alcohol consumption, clinical subtype, neurological site of first manifestation, month of assessment, medication after baseline, whether medication was changed during the study, and center variability. Differences in baseline severity were adjusted by using the baseline MSSS and the number of Gd-enhancing lesions at baseline as covariates. Adjustment for center was omitted when analyzing the effect of latitude.

pathway has been demonstrated to reduce disease severity in systemic lupus erythematosus (59). In contrast, MS is associated with a reduced type I IFN signature and patients respond positively to IFN-β therapy (28).

Furthermore, although sun exposure seems to be beneficial for MS patients, it is also important to consider individual patient characteristics, such as skin type and photosensitivity, and we therefore also investigated modulatory effects of photosensitivity-associated MCIR variants. In line with the concept of weak and strong MCIR variant alleles (32), only the high-penetrance variant rs1805008(C>T) showed a significant effect on self-reported skin reaction to sun exposure, whereas no association was found for rs885479(G>A) and rs2228479(G>A). The inverted effect of latitude on the number of Gd-enhancing lesions in carriers and noncarriers of the rs1805008 variant is in line with the observation of increased photosensitivity and a higher grade of inflammation induced through sun exposure, combined with the reduced responsiveness to anti-inflammatory stimuli of α-melanocyte–stimulating hormone in carriers of MCIR variant alleles (60, 61). The result should not be confounded by the major MS risk allele HLA-DRB1*15:01, since rs1805008 has been shown not to be in linkage disequilibrium with rs3135005, a nearly perfect proxy for HLA-DRB1*15:01 (62). The fact that this inverted association was not present across
read-outs could be due to the fact that there was no evidence for correlation between the MSSS and the number of Gd-enhancing lesions. Weak or missing correlation between MRI activity and disability has been described previously, especially for early disease forms (63). Furthermore, as the effects of MC1R in this study were only nominally significant, the results must be interpreted with care and require confirmation in larger cohorts.

Limitations of the study were that no information regarding recent holidays abroad (e.g., in areas with very high or very low sun exposure), no information regarding individual clothing behavior, and no information regarding the use of sunscreen was available. However, as there was a strong correlation between sampling de-seasonalized serum vitD and latitude in both cohorts, no major bias seems to have been introduced by these factors.

In summary, this study provides evidence for an effect of UVR on severity and disease worsening in established MS. Although excessive sun exposure is not recommended due the risk of skin cancer, this argues for beneficial effects of moderate sun exposure in MS. Mechanistically, vitD is supported as one of the main mediators of UVR-effects, but a role for the type I IFN and the MC1R pathway is brought up, as well. Differential effects of UVR in carriers and noncarriers of MC1R variants were observed, suggesting detrimental effects of UVR in sun-sensitive patients. Previous therapy with IFN-β reduced the effect of latitude on severity and also seemed to nullify the association.
Fig. 5. Transcriptional effects of UVB-phototherapy in immune cells. (A) MS patients had been treated with UVB-phototherapy during the course of our 2014 pilot study (18). PBMC samples of five patients before and 6 wk after phototherapy (10 samples in total) have been used to isolate CD4$^+$ T cells, CD8$^+$ T cells, B cells, and monocytes, that were then subjected to RNA-isolation and RNA-seq with subsequent bioinformatics analyses, including differential expression analysis and gene set enrichment analysis (overrepresentation analysis). (B–E) Labeled, volcano plots for CD4$^+$ T cells, CD8$^+$ T cells, monocytes, and B cells. (F–I) Before and after plots for exemplary genes associated with either the vitD or the type I IFN pathway, regulated by phototherapy in respective cell types. (J–M) Venn diagrams for the overlap between significantly regulated genes in the respective cell types and the vitD and type I IFN gene sets (extracted from wikipathways). P values were calculated from distribution-free permutation tests. The numbers for the reference gene sets refer to the number of genes belonging to the reference gene set and that have detectable expression in the respective cell type.

8o of 12 | PNAS Ostkamp et al.
https://doi.org/10.1073/pnas.2018457118 Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
between latitude and vitD levels. This suggests that the effect of latitude is at least in part mediated through vitD. This is also complemented by the up-regulation of the vitD and the type 1 IFN pathway in immune cells of UVB-treated MS patients, which suggests involvement of both pathways in the mediation of UVR-effects.

Methods

Patients. Data from the NationMS cohort, a prospective multicenter observational study, were used. In total, clinical data of 946 CIS/RRMS patients recruited between 2010 and 2017 in 21 centers in Germany, were obtained (64). Patients were followed-up and longitudinal data are available for 798 patients (Fig. 1). Included were patients with age ≥ 18 y, who were diagnosed with either CIS with fulfillment of three Barkhof criteria or confirmed RRMS according to revised 2005 McDonald criteria. All patients were treatment-naive at baseline with onset of symptoms no longer than 2 y before inclusion. The study was approved by the lead ethics committee (Ethik-Kommission der Ruhr-Universität Bochum, registration no. 3714-10) and all local committees. Informed written consent was obtained from all participants and the study was performed according to the Declaration of Helsinki. For replication, data of 990 patients from the BIONAT cohort (Study identifier: NCT00942214), a French, multicenter cohort, at their baseline assessment, were acquired (65). BIONAT patients were not treatment-naive before inclusion. Study investigators for NationMS and BIONAT can be found in SI Appendix. For RNA-seq, PBMC of five patients from our 2014 pilot study were used (18).

Genotyping and Estimation of Population Stratification. Genotyping and QC were performed as previously published (66, 67). Briefly, genotyping was performed using an Illumina OmniExpress chip and QC was performed in PLINK v1.90. Genotypes for the most common MC1R variants were extracted (rs1800087=C>T, rs885479=G>A, rs2228479=G>A), and population stratification was calculated by multidimensional scaling as previously published (66).

Serum vitD Measurements. For NationMS, vitD was measured as the serum level of 25(OH)D$_{2+3}$. Measurement was performed in NationMS for n = 761 patients with a commercially available kit for liquid chromatography-mass spectrometry (LC-MS/MS) (Recipe on a Shimadzu 8040 LC-MS/MS instrument coupled to a UHPLC system (Nexera, Shimadzu). For BIONAT, total 25(OH)D$_{2+3}$ measurements were available for 579 patients. Total vitD has been measured using a commercially available electro-chemiluminescence competitive 25-hydroxyvitamin D binding assay (Cobas, Roche), and quantified on a Roche Cobas 8000 e602 analyzer (Roche Diagnostics). As food-derived vitD$_2$ only contributes little to total serum vitD levels, there are only minimal differences between total vitD and vitD$_2$ serum levels.

Questionnaire on Photosensitivity. Of the NationMS cohort, 229 patients were asked to report their skin potential reaction to sunlight at noon for 1 h without the use of sunscreen in summer. Possible answers were “tan,” “sunburn with a delayed tan,” “sunburn without tan and without blisters,” and “sunburn without tan and with blisters.” Patients were asked to report skin reddening, a feeling of heat and itching after 12 to 24 h as a sunburn, and liquid-filled skin alterations with a diameter ≥ 5 mm as blisters. The resulting variable was treated as ordinal.

Statistical Analysis. Disease severity outcomes were the MSSS and the number of Gd-enhancing lesions (baseline). For longitudinal analyses, the increase/decrease in EDSS 2 y after baseline and the time to relapse were assessed. Explanatory variables were the two measures of UVR-exposure vitD and latitude. For further confirmation, satellite data from NASA’s ozone monitoring instrument-dataset were used to generate coordinate- and time-specific estimates of UVR exposure for each patient (methodology and results are reported in the SI Appendix, Supplementary Methods and Table S3). The MSSS was modeled as a continuous variable and the influence of the UVR-exposure measure was assessed using linear models. In the NationMS cohort these analyses were adjusted for age, sex, body mass index (BMI = weight/height$^2$), smoking (yes/no), alcohol (yes/no), month of assessment (treated as a categorical variable with 12 factor-levels), clinical subtype (CIS or RRMS), and the site/symptom of first disease manifestation (coded as categorical) (SI Appendix, Table S4). A random intercept was used to adjust for center variability, which was omitted when assessing the influence of latitude (latitude is intrinsic to the variability between centers and inclusion would lead to unresolvable multicollinearity). For the BIONAT cohort, these analyses were adjusted for age, sex, month of assessment, sitesymptom of first manifestation, and prior medication (other covariates not available for BIONAT). Center variability was treated as in the NationMS cohort. For BIONAT, the interaction of vitD or latitude and prior treatment was tested as well, followed by subgroup analyses to obtain subgroup-specific estimates, as some medications have been shown to modulate vitD synthesis (29).

The number of Gd-enhancing lesions in NationMS was modeled using a zero-inflated negative binomial-model to account for overdispersion. Confounder-adjustment was done as in the linear model. Plots for Gd-enhancing lesions include a left y axis, showing the observed number of lesions, and a right y axis, showing the mean number of lesions over x. The influence of the MC1R genotype on skin reaction to sun exposure was modeled using cumulative link models (ordinal regression) and adjusted for age, sex, BMI, alcohol consumption, smoking, and population stratification (first three multidimensional scaling components). To assess whether MC1R genotype modifies the effect of UVR exposure on severity, an interaction term between MC1R genotype and measures of sun exposure (latitude or vitD) was added to the models for disease severity and adjusted as the prior models for disease severity plus population stratification. To assess the influence of vitD and latitude on the risk for relapses in the NationMS cohort, hazard ratios for relapses were performed, adjusting for baseline UVR-exposure measures was assessed using linear models. In the NationMS cohort, the models for disease severity plus initial medication after baseline (therapy was initiated after baseline visit) and for whether medication was changed during the course of the study. Medications were treated as substance groups (e.g., IFN-β containing formulations from different suppliers were grouped as one IFN-β group). The difference between the EDSS 2 y after baseline and the baseline EDSS was calculated and declared as ΔEDSS. The ΔEDSS was modeled using linear and linear mixed models and adjusted as the baseline model plus the type of medication initiated after baseline visit and whether medication was changed during the study. Additionally, the models were adjusted for the number of lesions and the MSSS at baseline to account for differences in baseline severity and disease duration. Model fit was assessed by inspection of scaled quantile residuals (68). Model coefficients, Cis, and P values were reported from fully adjusted models with significance threshold of α = 0.05 using two-sided tests. Genetic analyses of the MC1R genotype that were not of confirmatory nature (i.e., assessing disease severity and not skin reaction) were assessed for genome-wide significance (α = 5 × 10$^{-8}$).

UVB Phototherapy. Patient samples from a previous study were used where patients had been irradiated with narrow-band UVB (311 nm). Irradiation had been performed in a chamber for phototherapy equipped with Philips TL-01 lamps (PDT 1200; Waldmann) for 6 wk (five sessions per week). Individual minimal erythema doses were determined and 60% of minimal erythema dose was used as the starting point. Per session, the dose was then increased by 100 mJ/cm$^2$ until either the maximum dose (900 mJ/cm$^2$) was reached or erythema occurred. A detailed description can be found in the original study (18).

RNA-Seq Analysis. RNA-seq was performed using samples of five patients from our 2014 pilot study (18). PBMC samples were sorted for CD4 T cells, CD8 T cells, B cells, and monocytes. Samples were then prepared for sequencing using reagents from New England Biolabs and sequenced on an Illumina NextSeq, 500 machine. Bioinformatic analysis was done in R using Kallisto and edgeR. Results from Kallisto quantification can be found in Datasets S7–10. Pathway analysis was performed using reference gene sets from wikipathways for permutation tests. A detailed description of the RNA-seq workflow can be found in SI Appendix, SI Supplementary Methods.

Software. Statistical analyses were conducted in R v3.6.0 using the packages stats, lme4, glmnTMB, ordinal, and DHARMa. To extract and process data from NASA’s ozone monitoring instrument dataset, the package RNetCDF was used. The remaining data were manipulated and plotted using the R packages tidyR, ggplot2, and TColorBrewer. For population stratification estimation, PLINK v1.0b5.2 was used. For analysis of RNA-seq data, Kallisto and edgeR were used. For pathway extraction from wikipathways, the package RSQLite was used.

Data Availability. Data and R code is available from the authors upon reasonable request. Full results from RNA-seq can be found in Datasets S1–S10.
A.S. received speaker honoraria and/or travel compensation for activities with Amicis Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diaomed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva; his research is funded, in part, by the BMGF, DFG, Else Kröner-Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, IFK Zürich, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Genzyme, ImmunoCed, Novartis, Ono, Roche, Sanoﬁ-Sanoﬁ, Merck Serono, Novartis, Teva, and personal fees from Actelion, Biogen, Genzyme-Sanofi, Medday, Merck Serono, Novartis, Roche, and Teva. T.K. has received research grants and/or compensation from Bayer Healthcare, Biogen, Merck, Novartis, Sanoﬁ-Aventis/Genezyme, Roche, and Biogen, as well as grants support from Bayer Schering AG, Novartis, and Chugai Pharma. U.Z. has received grants from DFG, BMWF, the European Research Council, BMBF, the European Research Council, Janssen and personal consulting fees from Pfizer, Biogen, and Sanofi; he has served as a steering committee member of DFG, CorTec, and Pettenkofer Institute. F.Z. and F.B. have received grants from the European Union, European Research Council, BMBF, and DFG; C.S. has served on steering committees from Bayer Healthcare, Biogen, GNeuro, MedImmune, Merck, Novartis, Olexa, Receptos, Sanoﬁ, Roche, Sanoﬁ-Aventis, CSL Behring, OCTAPHARM, and CorTec GmbH. F.Z. has received funds for scientific consultation or research by DFG, BMBF, the Pharmaceutical Management Science Association, Novartis, Octapharma, Merck Serono, ONO Pharma, Biogen, Genzyme, Sanoﬁ, Roche, Sanofi Aventis; A.S.-M. has received travel expenses and research support from Novartis. C.C.G. has received speaker honoraria and travel expenses for attending meetings with Biogen, Euroimmun, Genzyme, Mylan, Novartis Pharma GmbH, and Bayer Health Care, none related to this study; her work is funded by Biogen, Novartis, the BMGF (GV 161603a), the DFG (GR34964-31, SFB Transregio 128 A09), the European Union (Horizon2020, ReStoRe), the IZKF, and the Innovative Medizinische Forschung. D.B. receives lectures, congress invitation, board participation with Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. B.T. has received personal speaker honoraria and travel compensation from Biogen, Biogen, Fresenius Medical Care, GSK, Merck, Novartis, and Roche; he has received personal honoraria for speaking at advisory boards or other activities with Biogen, Biogen, Fresenius Medical Care, GSK, Merck, Novartis, and Roche; and he has received speaker honoraria and compensation from Bayer Healthcare, Biogen, Novartis, Akada, and Merck; h has served as section editor for the Journal of Neurology, Psychiatry, and Brain Research; H.T. and G.P. have received personal compensation from Merck, Biogen, Bayer, Roche, Biogen, Novartis, Sanofi-Aventis/Genezyme, Roche, and Biogen, as well as grant support from Biogen, GPeuro, Genzyme, Mylan, Novartis, Sanofi Aventis, and Biogen. C.L. received personal compensation from Biogen, Novartis, Sanoﬁ-Aventis/Genezyme, Roche, and Biogen, as well as grant support from Novartis and Merck. F.W. received personal compensation from Biogen, and Merck.
served on the scientific advisory board of Genzyme, Merck Serono, and Novartis; he has received travel funding and/or speaker honoraria from Bayer, Biogen, Teva, Merck Serono, Novartis, and Pfizer; he is employed by Sana and received research support from the BMBF, Merck Serono, and Novartis. F.P. reported other fees from Bayer, Novartis, Biogen-Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, and Alexion. J.I. received consulting fees from Sanofi Genzyme, Biogen-Idec, MedImmune, and Shire, and Alexion, and research support from Bayer, Novartis, Biogen Idex, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, the German Research Council, Werner Stiftung, German Medical Education and Research, Arthur Arnstein Stiftung Berlin, EU IP Framework Program, Alzheimer Association, and Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the United States. B.H. has served on scientific advisory boards for Novartis; he has served as data monitoring and safety committee member for AllergyCare and TG therapeutics; he or his institution has received speaker honoraria from Desitin; he holds part of two patents, one for the detection of antibodies against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibody activity. F.L. has served on the advisory board of Roche and received travel funding from Teva. M.M. received research support from Merck Serono and Novartis as well as travel expenses for attending meetings from Merck Serono. K.-L.H. has received research support (to Technische Universität München) from Novartis, honoraria from Novartis and F. Hoffmann-La Roche, and compensation for travel expenses from Merck Serono.

11. J. J. Bernard, R. L. Gallo, J. Krutmann, Photoimmunology: How ultraviolet radiation has received research support (to Technische Universität München) from Novartis, honoraria from Novartis and F. Hoffmann-La Roche, and compensation part of two patents, one for the detection of antibodies against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibody activity. F.L. has served on the advisory board of Roche and received travel funding from Teva. M.M. received research support from Merck Serono and Novartis as well as travel expenses for attending meetings from Merck Serono. K.-L.H. has received research support (to Technische Universität München) from Novartis, honoraria from Novartis and F. Hoffmann-La Roche, and compensation for travel expenses from Merck Serono.